Evidence map›Paper›PMID 40725189›Full record

ArticleInternational journal of molecular sciences2025

Seed-Specific Silencing of Abundantly Expressed Soybean Bowman-Birk Protease Inhibitor Genes by RNAi Lowers Trypsin and Chymotrypsin Inhibitor Activities and Enhances Protein Digestibility.

Wonseok Kim, Sunhyung Kim, Hari B Krishnan

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Wonseok KimDivision of Plant Science and Technology, University of Missouri, Columbia, MO 65211, USA.
Sunhyung KimDivision of Plant Science and Technology, University of Missouri, Columbia, MO 65211, USA.
Hari B KrishnanDivision of Plant Science and Technology, University of Missouri, Columbia, MO 65211, USA.ORCID 0000-0001-6437-3672

Funding

USDA-ARS 5070-21000-044-000D
6 · The paper itself

Abstract

Soybean meal (SBM) is extensively used as a predominant protein source in animal feed. However, raw soybean cannot be directly utilized in animal feed, due to the presence of the Kunitz trypsin inhibitor (KTi) and the Bowman-Birk protease inhibitor (BBi). These antinutritional factors inhibit the digestive enzymes in animals, trypsin and chymotrypsin, resulting in poor animal performance. To inactivate the activity of protease inhibitors, SBM is subjected to heat processing, a procedure that can negatively impact the soybean protein quality. Thus, it would be beneficial to develop soybean varieties with little or no trypsin inhibitors. In this study, we report on the creation of experimental soybean lines with significantly reduced levels of Bowman-Birk protease inhibitors. RNA interference (RNAi) technology was employed to generate several transgenic soybean lines. Some of these BBi knockdown soybean lines showed significantly lower amounts of both trypsin and chymotrypsin inhibitor activities. Western blot analysis revealed the complete absence of BBi in selected RNAi-derived lines. RNA sequencing (RNAseq) analysis demonstrated a drastic reduction in the seed-specific expression of

Indexed as

ChymotrypsinGlycine maxRNA InterferenceSeedsTrypsin Inhibitor, Bowman-Birk SoybeanDigestionGene Expression Regulation, PlantPlants, Genetically ModifiedSoybean ProteinsTrypsinTrypsin InhibitorsChymotrypsinSoybean ProteinsTrypsinTrypsin Inhibitor, Bowman-Birk SoybeanTrypsin Inhibitorsantinutritional factorsBowman–Birk inhibitorconfocal fluorescence immunolabelingGlycine max (L. (Merr))protein digestibilityRNA interferencesoybean

Identifiers

PMID40725189
PMCPMC12294982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.